Backs FY25 adjusted combined R&D, APR&D, SG&A expenses view $4.9B-$5B.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex will not progress VX-993 into pivotal development
- Vertex Pharmaceuticals reports Q2 EPS $3.99, consensus $4.25
- Vertex options imply 6.0% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, August 04, 2025
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?